How to Add GLP-1 Weight Loss to Your Med Spa (Legally) in 2026

GLP-1 medications have become the most-searched aesthetic-adjacent service in North America — and med spas are the natural home for them. Here is what it actually takes to offer semaglutide or tirzepatide legally, without guessing.

Why Med Spas Are the Right Venue for GLP-1 Programs

Your clients are already coming to you to look and feel their best. Weight management fits the brand, the relationship, and the cadence. Monthly follow-up visits, body-composition monitoring, and lifestyle coaching are things med spas do well. The challenge is not the demand — it is the regulatory architecture required to prescribe a controlled pharmaceutical.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are prescription medications. That single fact determines every compliance decision you need to make. You cannot dispense or administer them without a valid prescription from a licensed prescriber, and that prescriber must have an established patient-provider relationship, not just a rubber-stamped telehealth encounter.

The Legal Foundation: Corporate Practice of Medicine

Most states have some form of Corporate Practice of Medicine (CPOM) doctrine, which prohibits a non-physician-owned entity from employing physicians or exercising control over their clinical decisions. This is not a technicality — it is the core legal constraint for any med spa trying to add prescription services.

The standard solution is the PC-MSO model:

• Professional Corporation (PC) — a physician-owned entity that employs or contracts with the prescribing clinicians, owns the patient-care relationship, and bears clinical and regulatory liability.
• Management Services Organization (MSO) — a separate entity (which your business contracts with) that handles operations, technology, billing support, marketing infrastructure, and administrative staffing. The MSO cannot direct clinical decisions.

Under this structure, your med spa enters a management services agreement with an MSO. The MSO supports a physician-owned PC that handles all prescribing. The physician retains full clinical authority — who gets prescribed, at what dose, with what monitoring plan. Your business gets a compliant, operational weight-management program.

"The PC-MSO model is not a loophole — it is the established, state-sanctioned way for non-physician businesses to co-locate with physician-led care. The key is that the physician genuinely controls every clinical decision."

What Services a Med Spa Can and Cannot Do

Let's be precise. Under a properly structured PC-MSO arrangement, here is the service scope:

What the physician-owned PC handles (clinical layer)

• Patient intake, history, and screening (BMI, contraindications, comorbidities)
• Prescription issuance and pharmacy routing
• Ongoing titration and monitoring decisions
• Adverse event management and clinical documentation

What your med spa can operate (administrative layer)

• Patient-facing scheduling and intake coordination
• Body-composition tracking, progress photography, and wellness coaching
• Nutritional education and lifestyle programming (non-medical)
• Product and supplement retail (non-prescription)
• Facility space, staffing (non-clinical), and marketing

The line that must never blur: your business does not direct prescribing decisions, select medications, or override the physician's clinical judgment. The MSO agreement must make this explicit.

Prescriber Requirements for GLP-1 Programs

Every state has its own scope-of-practice rules. In most states, the following practitioners can prescribe GLP-1 medications:

• MD or DO (physician) — unrestricted in all states
• Nurse Practitioner (NP) — full independent authority in about 27 states; requires physician supervision or collaboration in the rest
• Physician Assistant (PA) — collaborative agreement or supervision required in most states

State-specific supervision ratios, geographic proximity requirements, and collaborative agreement rules vary significantly. See our companion article on medical director requirements by state for a state-by-state breakdown.

One nuance specific to GLP-1 programs: if your current medical director arrangement is scoped to aesthetics only (lasers, injectables, peels), it almost certainly does not cover prescribing obesity medicine or internal-medicine-adjacent therapeutics. You likely need an additional or amended agreement before you add weight management.

Compounding Pharmacies: The 2026 Landscape

In 2024–2025, semaglutide and tirzepatide were on FDA's drug shortage list, which allowed 503A compounding pharmacies to prepare patient-specific compounded versions. FDA removed semaglutide from the shortage list in early 2025 and has signaled similar action on tirzepatide.

What that means for your program in 2026:

• 503A compounders can only prepare compounded semaglutide pursuant to individual patient prescriptions and generally cannot use it for office stock or batch dispensing.
• 503B outsourcing facilities operate under different — and more permissive — rules but are subject to FDA oversight and must comply with current good manufacturing practice (cGMP).
• Branded commercial products (Ozempic, Wegovy, Mounjaro, Zepbound) remain available but face supply constraints and prior-authorization friction through commercial insurance.

Intake, Monitoring, and Patient Safety Protocols

GLP-1 programs are not high-risk when run properly, but they are not zero-risk either. A compliant program includes:

Pre-treatment screening

• Medical history including personal or family history of medullary thyroid carcinoma or MEN2 (absolute contraindications for GLP-1 agonists)
• Baseline labs: metabolic panel, HbA1c, lipids, thyroid function
• BMI and body-composition baseline
• Current medications (especially insulin, sulfonylureas — hypoglycemia risk)

Ongoing monitoring cadence

• Monthly prescriber check-ins (in-person or synchronous telehealth depending on state rules)
• Quarterly labs for programs extending beyond 90 days
• Adverse event reporting pathway clearly defined in the clinical protocol

Building these protocols from scratch is expensive and risky. MDside's nationwide physician network comes with standardized clinical protocols validated by physicians with obesity medicine experience, which reduces your legal exposure and speeds time to launch.

Marketing GLP-1 Services Without Getting Into Trouble

The FTC and state attorneys general are actively monitoring medical weight-loss marketing. A few rules that apply regardless of your state:

• No outcome guarantees: Do not promise specific weight-loss numbers. Clinical trials show population-level averages; individuals vary.
• No before-and-after deception: Before-and-after images must represent actual patients with appropriate disclosures and written consent.
• Accurate drug descriptions: Do not describe compounded products as equivalent to branded medications unless the prescribing physician has made that clinical determination.
• Disclose the physician relationship: Patients must understand they are receiving care from a physician-owned practice, not from your spa business entity.

How to Structure the Launch

A practical launch sequence for a med spa adding GLP-1 services:

1. Legal review — Have counsel confirm your state's CPOM rules and any specific medical weight-management regulations (some states license "weight-loss clinics" separately).
2. Secure the physician structure — Either contract with an existing PC-MSO platform like MDside or build your own physician-owned PC and MSO (the latter requires significant legal and operational investment).
3. Protocol development — Work with the supervising physician to define screening criteria, prescribing protocols, titration schedules, and adverse event procedures.
4. Pharmacy relationships — The physician determines appropriate pharmacy routing; your operations team facilitates prescription processing workflows.
5. Staff training — Clinical staff working under the PC get trained on the protocol; your non-clinical staff learn the intake and coordination workflows.
6. Soft launch — Start with a small patient cohort to stress-test workflows before opening broadly.

If you want to skip the from-scratch build, book a discovery call to see how MDside compresses this timeline using infrastructure already built for exactly this use case.

What This Costs to Build vs. What It Costs to Partner

Building a compliant GLP-1 program independently typically involves:

• Attorney fees for PC formation and MSO drafting: $8,000–$25,000+
• Physician recruitment and credentialing: 60–120 days and significant ongoing cost
• EMR and clinical documentation software: $300–$800/month
• Protocol development with a qualified physician: $3,000–$10,000

Partnering with an established PC-MSO platform converts most of that to a flat management fee — and eliminates the single biggest risk: discovering 18 months in that your structure has a CPOM problem. MDside's security and compliance infrastructure is built specifically to pass the scrutiny that regulators and payers apply to medical weight-management programs.